No headlines found.
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Globe Newswire (Thu, 4-Apr 7:00 AM ET)
Globe Newswire (Tue, 26-Mar 7:00 AM ET)
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Globe Newswire (Wed, 28-Feb 7:00 AM ET)
Globe Newswire (Mon, 26-Feb 8:00 AM ET)
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Globe Newswire (Tue, 20-Feb 7:00 AM ET)
Globe Newswire (Tue, 13-Feb 7:00 AM ET)
Globe Newswire (Thu, 8-Feb 7:00 AM ET)
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
Globe Newswire (Thu, 1-Feb 7:00 AM ET)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Krystal Biotech trades on the NASDAQ stock market under the symbol KRYS.
As of April 18, 2024, KRYS stock price declined to $163.97 with 255,160 million shares trading.
KRYS has a beta of 0.70, meaning it tends to be less sensitive to market movements. KRYS has a correlation of 0.02 to the broad based SPY ETF.
KRYS has a market cap of $4.64 billion. This is considered a Mid Cap stock.
Last quarter Krystal Biotech reported $42 million in Revenue and $.30 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.67.
In the last 3 years, KRYS stock traded as high as $189.97 and as low as $38.86.
The top ETF exchange traded funds that KRYS belongs to (by Net Assets): VTI, VB, IWM, VBR, XBI.
KRYS has outperformed the market in the last year with a return of +86.2%, while the SPY ETF gained +22.3%. In the last 3 month period, KRYS beat the market returning +30.1%, while SPY returned +6.1%. However, in the most recent 2 weeks KRYS has underperformed the stock market by returning -7.8%, while SPY returned -3.8%.
KRYS support price is $165.91 and resistance is $173.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRYS stock will trade within this expected range on the day.